Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant WNV-HCD86 oncolytic immunotherapy in advanced solid tumors
ChiCTR2300070741Phase 2Not yet recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Apr 2023
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant WNV-HCD86 in laryngeal cancer, small cell lung cancer (SCLC), liver cancer and 4 more (9 arms), sponsored by Hubei Cancer Hospital. Primary endpoints: Dose-limiting toxicity, Overall response rate and 1 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
recombinant WNV-HCD86
03
Conditions
laryngeal cancersmall cell lung cancer (SCLC)liver cancerbreast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300070741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070741.